These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
AAV vectors are widely used in gene therapy for their strong therapeutic potential
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Initiative focuses on early diagnosis, gut health awareness and long-term gluten-free care for children with celiac disease
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
